Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Grants Astellas/Pfizer’s XTANDI® Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

americanpharmaceuticalreviewAugust 23, 2019

Tag: FDA , priority , Prostate Cancer

PharmaSources Customer Service